Antithrombotic and antiplatelet activities of small-molecule alkaloids from Scolopendra subspinipes mutilans

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lee, Wonhwa ^a,b   Lee, Jung In ^c   Kulkarni, Roshan ^c   Kim, Mi Ae ^d   Hwang, Jae Sam ^d   Na, Min Kyun ^c   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Chungnam National University   (South Korea)

^d National Institute of Animal Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; FIBRIN; FIBRINOLYTIC AGENT; HERBACEOUS AGENT; INDOLEACETIC ACID; INDOLEACETIC ACID DERIVATIVE; POLYAMINE; QUINOLINE DERIVATIVE; SCOLOPENDRA; THROMBIN;

ACYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; ISOLATION AND PURIFICATION; MALE; METABOLISM; MOUSE; PARTIAL THROMBOPLASTIN TIME; PATHOLOGY; POLYMERIZATION; PROTHROMBIN TIME; PULMONARY EMBOLISM; THROMBOCYTE AGGREGATION; THROMBOSIS;

ACYLATION; ALKALOIDS; ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUGS, CHINESE HERBAL; FACTOR XA; FIBRIN; FIBRINOLYTIC AGENTS; INDOLEACETIC ACIDS; MALE; MICE; MICE, INBRED C57BL; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; POLYAMINES; POLYMERIZATION; PROTHROMBIN TIME; PULMONARY EMBOLISM; QUINOLINES; THROMBIN; THROMBOSIS;

EID: 84959421792     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21956     Document Type: Article

References (57)

1. Fares, A. Winter cardiovascular diseases phenomenon. N. Am. J. Med. Sci. 5, 266-279 (2013).
2. Davi, G., & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
3. Cai, M. D., et al. Scolopendra subspinipes mutilans attenuates neuroinflammation in symptomatic hSOD1G93A mice. J. Neuroinflammation. 10, 131/131-131/139, 139 pp (2013).
4. Ma, W., Zhang, D., Zheng, L., Zhan, Y., & Zhang, Y. Potential roles of Centipede Scolopendra extracts as a strategy against EGFRdependent cancers. Am. J. Transl. Res. 7, 39-52 (2015).
5. Kong, Y., et al. Antithrombotic Peptides from Scolopendra subspinipes mutilans Hydrolysates. In.t J. Pept. Res. Ther. 20, 245-252 (2014).
6. Kong, Y., Huang, S. L., Shao, Y., Li, S., & Wei, J. F. Purification and characterization of a novel antithrombotic peptide from Scolopendra subspinipes mutilans. J. Ethnopharmacol. 145, 182-186 (2013).
7. Kong, Y., et al. A Novel Factor Xa-Inhibiting Peptide from Centipedes Venom. Int. J. Pept. Res. Ther. 19, 303-311 (2013).
8. Liu, Z. C., et al. Venomic and transcriptomic analysis of centipede Scolopendra subspinipes dehaani. J. Proteome. Res. 11, 6197-6212 (2012).
9. Yang, S., et al. Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models. Proc. Natl. Acad. Sci. USA 110, 17534-17539 (2013).
10. Moon, S. S., et al. Jineol, a cytotoxic alkaloid from the centipede Scolopendra subspinipes. J. Nat. Prod. 59, 777-779 (1996).
11. Fu, Y. D., Li, Z. L., Pu, S. B., & Qian, S. H. Two new compounds from Scolopendra multidens Newport. J. Asian. Nat. Prod. Res. 15, 363-367 (2013).
12. Yoon, M. A., et al. Antioxidant effects of quinoline alkaloids and 2, 4-Di-Tert-butylphenol isolated from Scolopendra subspinipes. Biol. Pharm. Bull. 29, 735-739 (2006).
13. Noda, N., Yashiki, Y., Nakatani, T., Miyahara, K., & Du, X. M. A novel quinoline alkaloid possessing a 7-benzyl group from the centipede, Scolopendra subspinipes. Chem. Pharm. Bull. 49, 930-931 (2001).
14. Abed, C., et al. A new hydroxylated nonaprenylhydroquinone from the Mediterranean marine sponge Sarcotragus spinosulus. Mar. Drugs. 9, 1210-1219 (2011).
15. Derosa, S., Crispino, A., Degiulio, A., Iodice, C., & Milone, A. Sulfated polyprenylhydroquinones from the sponge ircinia-spinosula. J. Nat. Prod. 58, 1450-1454 (1995).
16. McCormick, K. D., & Meinwald, J. Neurotoxic acylpolyamines from spider venoms. J. Chem. Ecol. 19, 2411-2451 (1993).
17. Schroeder, F. C., et al. NMR-spectroscopic screening of spider venom reveals sulfated nucleosides as major components for the brown recluse and related species. Proc. Natl. Acad. Sci. 105, 14283-14287 (2008).
18. Moon, S.-S., et al. Jineol, a Cytotoxic Alkaloid from the Centipede Scolopendra subspinipes. J. Nat. Prod. 59, 777-779 (1996).
19. Siuda, J. F. Chemical defense mechanisms of marine organisms. Identification of 8-hydroxy-4-quinolone from the ink of the giant octopus, Octopus dofleini martini. Lloydia 37, 501-503 (1974).
20. Evidente, A., Iacobellis, N. S., & Sisto, A. Isolation of indole-3-Acetic acid methyl ester, a metabolite of indole-3-Acetic acid from Pseudomonas amygdali. Experientia 49, 182-183 (1993).
21. Fu, Y.-D., Li, Z.-L., Pu, S.-B., & Qian, S.-H. Two new compounds from Scolopendra multidens Newport. J. Asian Nat. Prod. Res. 15, 363-367 (2013).
22. Yoon, M.-A., et al. Antioxidant effects of quinoline alkaloids and 2, 4-Di-Tert-butylphenol isolated from Scolopendra subspinipes. Biol. Pharm. Bull. 29, 735-739 (2006).
23. Noda, N., Yashiki, Y., Nakatani, T., Miyahara, K., & Du, X.-M. A novel quinoline alkaloid possessing a 7-benzyl group from the centipede, Scolopendra subspinipes. Chem. Pharm. Bull. 49, 930-931 (2001).
24. Diehl, K. H., et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21, 15-23 (2001).
25. Izuhara, Y., et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler. Thromb. Vasc. Biol. 28, 672-677 (2008).
26. Wei, A. H., Schoenwaelder, S. M., Andrews, R. K., & Jackson, S. P. New insights into the haemostatic function of platelets. Br. J. Haematol. 147, 415-430 (2009).
27. Elzagallaai, A., Rose, S. D., & Trifaro, J. M. Platelet secretion induced by phorbol esters stimulation is mediated through phosphorylation of MARCKS: a MARCKS-Derived peptide blocks MARCKS phosphorylation and serotonin release without affecting pleckstrin phosphorylation. Blood 95, 894-902 (2000).
28. Sugo, T., Nakamikawa, C., Tanabe, S., & Matsuda, M. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. J. Biochem. 117, 244-250 (1995).
29. Rao, L. V., Rapaport, S. I., & Lorenzi, M. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71, 791-796 (1988).
30. Ghosh, S., et al. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J. Thromb. Haemost. 5, 336-346 (2007).
31. Philip-Joet, F., et al. Fibrinolytic and inflammatory processes in pleural effusions. Eur. Respir. J. 8, 1352-1356 (1995).
32. Schleef, R. R., Bevilacqua, M. P., Sawdey, M., Gimbrone, M. A., Jr., & Loskutoff, D. J. Cytokine activation of vascular endothelium. Effects on tissue-Type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 263, 5797-5803 (1988).
33. Hamaguchi, E., Takamura, T., Shimizu, A., & Nagai, Y. Tumor necrosis factor-Alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase-and nuclear factor-kappaB-Dependent pathways in cultured human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 307, 987-994 (2003).
34. Davie, E. W. Biochemical and molecular aspects of the coagulation cascade. Thromb. Haemost. 74, 1-6 (1995).
35. Davie, E. W., Fujikawa, K., & Kisiel, W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363-10370 (1991).
36. Quinn, C., Hill, J., & Hassouna, H. A guide for diagnosis of patients with arterial and venous thrombosis. Clin. Lab. Sci. 13, 229-238 (2000).
37. Lopez, S., Peiretti, F., Bonardo, B., Juhan-Vague, I., & Nalbone, G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152, 359-366 (2000).
38. Despotis, G. J., Gravlee, G., Filos, K., & Levy, J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 91, 1122-1151 (1999).
39. Jauch, E. C., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44, 870-947 (2013).
40. Esmon, C. T. The interactions between inflammation and coagulation. Br. J. Haematol. 131, 417-430 (2005).
41. Schouten, M., Wiersinga, W. J., Levi, M., & van der Poll, T. Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 83, 536-545 (2008).
42. Wells, P. S., Forgie, M. A., & Rodger, M. A. Treatment of venous thromboembolism. JAMA 311, 717-728 (2014).
43. Hirsh, J., et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 108, 258 S-275 S (1995).
44. Pereira, M. S., Melo, F. R., & Mourao, P. A. Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans?. Glycobiology 12, 573-580 (2002).
45. Bae, J. S., et al. Transforming Growth Factor beta-induced Protein Promotes Severe Vascular Inflammatory Responses. Am. J. Respir. Crit Care Med. 189, 779-786 (2014).
46. Ku, S. K., Han, M. S., Lee, M. Y., Lee, Y. M., & Bae, J. S. Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. BMB Rep. 47, 336-341 (2014).
47. Ku, S. K., & Bae, J. S. Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa. Arch. Pharm. Res. 37, 1454-1463 (2014).
48. Ku, S. K., & Bae, J. S. Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo. BMB Rep. 47, 376-381 (2014).
49. Kim, T. H., Ku, S. K., & Bae, J. S. Antithrombotic and profibrinolytic activities of eckol and dieckol. J. Cell. Biochem. 113, 2877-2883 (2012).
50. Dejana, E., Callioni, A., Quintana, A., & de Gaetano, G. Bleeding time in laboratory animals. II-A comparison of different assay conditions in rats. Thromb. Res. 15, 191-197 (1979).
51. Nowak, P., Zbikowska, H. M., Ponczek, M., Kolodziejczyk, J., & Wachowicz, B. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb. Res. 121, 163-174 (2007).
52. Kim, S. Y., et al. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hyporesponsive platelets by enhancing Akt phosphorylation. BMB Rep. 44, 140-145 (2011).
53. Lee, W., Ku, S. K., & Bae, J. S. Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin. Arch. Pharm. Res. 38, 893-903 (2015).
54. Goto, S., Tamura, N., & Ishida, H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J. Am. Coll. Cardiol. 44, 316-323 (2004).
55. Wu, C. C., Wu, C. I., Wang, W. Y., & Wu, Y. C. Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta Med. 73, 439-443 (2007).
56. Grynkiewicz, G., Poenie, M., & Tsien, R. Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450 (1985).
57. Bae, J. S. Antithrombotic and profibrinolytic activities of phloroglucinol. Food Chem. Toxicol. 49, 1572-1577 (2011).